keyword
MENU ▼
Read by QxMD icon Read
search

Ivabradine

keyword
https://www.readbyqxmd.com/read/29121737/ivabradine-well-tolerated-in-elderly-patients-with-systolic-heart-failure
#1
EDITORIAL
Christos Zivlas, Paul W X Foley
No abstract text is available yet for this article.
December 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/29121732/quality-of-life-improvement-in-older-patients-with-heart-failure-initiated-on-ivabradine-results-from-the-uk-multi-centre-live-life-prospective-cohort-study
#2
D Zachariah, D Stevens, G Sidorowicz, C Spooner, N Rowell, J Taylor, R Kay, M S Salek, P R Kalra
AIMS: LIVE:LIFE is a multi-centre, open-label, prospective observational cohort study assessing health-related quality of life (HRQoL) in older patients with chronic heart failure (CHF) following initiation of ivabradine. The primary endpoint is change in Minnesota Living with Heart Failure Questionnaire (MLWHFQ) total score after 6months. METHODS AND RESULTS: Consenting patients aged ≥70years with CHF, in whom ivabradine was initiated within its licensed indication, were enrolled...
December 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/29116618/treatment-of-stable-angina-with-a-new-fixed-dose-combination-of-ivabradine-and-metoprolol-effectiveness-and-tolerability-in-routine-clinical-practice
#3
Dimitar Divchev, Georg Stöckl
INTRODUCTION: In this prospective, multicenter, observational cohort study, the effectiveness and tolerability of the first fixed-dose combination (FDC) formulation of the selective heart rate reducing agent ivabradine and the beta-blocker metoprolol was evaluated in stable angina pectoris (AP) patients in a clinical practice setting. METHODS: Stable AP outpatients received a FDC of ivabradine and metoprolol (b.i.d.) for 4 months, in addition to cardiovascular standard therapy...
November 7, 2017: Cardiology and Therapy
https://www.readbyqxmd.com/read/29098508/pharmacological-heart-rate-lowering-in-patients-with-a-preserved-ejection-fraction-review-of-a-failing-concept
#4
REVIEW
Markus Meyer, Mehdi Rambod, Martin LeWinter
Epidemiological studies have demonstrated that high resting heart rates are associated with increased mortality. Clinical studies in patients with heart failure and reduced ejection fraction have shown that heart rate lowering with beta-blockers and ivabradine improves survival. It is therefore often assumed that heart rate lowering is beneficial in other patients as well. Here, we critically appraise the effects of pharmacological heart rate lowering in patients with both normal and reduced ejection fraction with an emphasis on the effects of pharmacological heart rate lowering in hypertension and heart failure...
November 3, 2017: Heart Failure Reviews
https://www.readbyqxmd.com/read/29098378/control-of-cardiac-chronotropic-function-in-patients-after-heart-transplantation-effects-of-ivabradine-and-metoprolol-succinate-on-resting-heart-rate-in-the-denervated-heart
#5
Rasmus Rivinius, Matthias Helmschrott, Arjang Ruhparwar, Ann-Kathrin Rahm, Fabrice F Darche, Dierk Thomas, Tom Bruckner, Philipp Ehlermann, Hugo A Katus, Andreas O Doesch
BACKGROUND: Patients after heart transplantation (HTX) present with sinus tachycardia due to graft denervation. As elevated heart rates negatively affect survival, the aim of this study was to analyze the effects of ivabradine vs metoprolol succinate on heart rate, left ventricular (LV) mass and survival following HTX. METHODS: This observational retrospective single-center study assessed 84 patients continuously receiving either ivabradine (n = 40) or metoprolol succinate (n = 44) within 2 years after HTX...
November 2, 2017: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/29066291/in-silico-assessment-of-the-effects-of-various-compounds-in-mea-hipsc-cm-assays-modeling-and-numerical-simulations
#6
Emanuela Abbate, Muriel Boulakia, Yves Coudière, Jean-Frédéric Gerbeau, Philippe Zitoun, Nejib Zemzemi
We propose a mathematical approach for the analysis of drugs effects on the electrical activity of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) based on multi-electrode array (MEA) experiments. Our goal is to produce an in silico tool able to simulate drugs action in MEA/hiPSC-CM assays. The mathematical model takes into account the geometry of the MEA and the electrodes' properties. The electrical activity of the stem cells at the ion-channel level is governed by a system of ordinary differential equations (ODEs)...
October 21, 2017: Journal of Pharmacological and Toxicological Methods
https://www.readbyqxmd.com/read/29046002/-optimal-diagnostics-and-therapy-for-microvascular-angina-pectoris
#7
Peter Ong, Udo Sechtem
Patients with microvascular angina are characterized by angina pectoris with proof of myocardial ischemia in the absence of any relevant epicardial stenosis and without myocardial disease (type 1 coronary microvascular dysfunction according to Crea and Camici). Structural and functional alterations of the coronary microvessels (diameter < 500 µm) are the reason for this phenomenon. Frequently such alterations are associated with cardiovascular risk factors. Patients with angina pectoris without epicardial stenoses represent for 10 - 50 % of all patients undergoing coronary angiography depending on the clinical presentation...
October 2017: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/29027608/ivabradine-in-postural-orthostatic-tachycardia-syndrome-preliminary-experience-in-children
#8
Grazia Delle Donne, Ferran Rosés Noguer, Jan Till, Tushar Salukhe, Sanjay K Prasad, Piers E F Daubeney
OBJECTIVE: Ivabradine is a selective and specific inhibitor of the I(f) current in the sinoatrial and atrioventricular nodes. It decreases heart rate and myocardial oxygen consumption at rest and during exercise. It is used in adults for management of heart failure and angina, but promising results have been obtained in postural orthostatic tachycardia syndrome (POTS). There is little experience of ivabradine in childhood, although it is used on a compassionate basis. Our aim was to review our experience of ivabradine in a retrospective evaluation of pediatric patients with POTS...
October 13, 2017: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29027329/duration-of-chronic-heart-failure-affects-outcomes-with-preserved-effects-of-heart-rate-reduction-with-ivabradine-findings-from-shift
#9
Michael Böhm, Michel Komajda, Jeffrey S Borer, Ian Ford, Christoph Maack, Luigi Tavazzi, Aurélie Moyne, Karl Swedberg
AIMS: In heart failure (HF) with reduced ejection fraction and sinus rhythm, heart rate reduction with ivabradine reduces the composite incidence of cardiovascular death and HF hospitalization. METHODS AND RESULTS: It is unclear whether the duration of HF prior to therapy independently affects outcomes and whether it modifies the effect of heart rate reduction. In SHIFT, 6505 patients with chronic HF (left ventricular ejection fraction of ≤35%), in sinus rhythm, heart rate of ≥70 b...
October 12, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/29017929/inappropriate-sinus-tachycardia-symptom-and-heart-rate-reduction-with-ivabradine-a-pooled-analysis-of-prospective-studies
#10
Sunil T Mathew, Sunny S Po, Udho Thadani
BACKGROUND: Inappropriate sinus tachycardia (IST) is debilitating despite available treatment. Off-label use of ivabradine for IST prompted this systematic analysis of existing data quality and sample size estimates for adequately powered studies. OBJECTIVE: To determine clinical efficacy of ivabradine in IST from pooled prospective studies. METHODS: Analysis included ivabradine studies for IST participants without structural heart disease and with follow-up of ≥2 weeks...
October 7, 2017: Heart Rhythm: the Official Journal of the Heart Rhythm Society
https://www.readbyqxmd.com/read/28984762/ivabradine-has-a-neutral-effect-on-mortality-in-randomized-controlled-trials
#11
REVIEW
Sheng Kang, Chong-Jian Li, Xu-Min Zhang
BACKGROUND: It has long been a controversial hotspot whether resting heart rate (RHR) is a risk factor or a marker for death. Ivabradine, a specific inhibitor of the If current in the sinoatrial node, is a pure RHR lowering agent. The study was aimed to investigate whether ivabradine would reduce more RHR, cardiovascular disease (CVD) mortality, and all-cause mortality than those placebo or beta-blockers. METHODS: The authors performed a meta-analysis of 8 randomized controlled clinical studies (with 40,357 participants), and 3 studies of those which were ivabradine versus placebo (36,069 participants) and other 5 studies ivabradine versus beta-blockers (4288 participants) were available...
October 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28982967/pharmacological-analysis-of-the-transmembrane-action-potential-configuration-in-myoepithelial-cells-of-the-spontaneously-beating-heart-of-the-ascidian-styela-rustica-in-vitro
#12
Vladimir A Golovko, Igor A Kosevich, Mikhail A Gonotkov
The mechanisms of action potential (AP) generation in the myoepithelial cells of the Tunicata heart are not yet well understood. Here, an attempt was made to elucidate these mechanisms by analyzing the effects of specific blockers of K(+), Na(+) and Ca(2+) currents on the configuration of transmembrane APs and their frequency in the spontaneously beating ascidian heart. In addition, an immunocytochemical analysis of heart myoepithelial cells was performed. Staining with anti-FMRF-amide and anti-tubulin antibodies did not reveal any nerve elements within the heart tube...
October 5, 2017: Journal of Experimental Biology
https://www.readbyqxmd.com/read/28973319/differential-effects-of-hcn-channel-block-on-on-and-off-pathways-in-the-retina-as-a-potential-cause-for-medication-induced-phosphene-perception
#13
Sebastian Bemme, Michael Weick, Tim Gollisch
Purpose: Phosphene perception is a characteristic side effect of heart rate-reducing medication that acts on hyperpolarization-activated cyclic nucleotide-gated (HCN) ion channels. It is hypothesized that these phosphenes are caused by blocking HCN channels in photoreceptors and neurons of the retina, yet the underlying changes in visual signal processing in the retina caused by the HCN channel block are still unknown. Methods: We examined the effects of pharmacologic HCN channel block on the encoding of visual signals in retinal ganglion cells by recording ganglion cell spiking activity from isolated mouse retinas mounted on multielectrode arrays...
September 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28958335/the-clinical-use-of-ivabradine
#14
REVIEW
Jacob S Koruth, Anuradha Lala, Sean Pinney, Vivek Y Reddy, Srinivas R Dukkipati
The clinical use of ivabradine has and continues to evolve along channels that are predicated on its mechanism of action. It selectively inhibits the funny current (If) in sinoatrial nodal tissue, resulting in a decrease in the rate of diastolic depolarization and, consequently, the heart rate, a mechanism that is distinct from those of other negative chronotropic agents. Thus, it has been evaluated and is used in select patients with systolic heart failure and chronic stable angina without clinically significant adverse effects...
October 3, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28930912/reducing-elevated-heart-rates-in-patients-with-multiple-organ-dysfunction-syndrome-with-the-if-funny-channel-current-inhibitor-ivabradine
#15
Sebastian Nuding, Jochen Schröder, Peter Presek, Andreas Wienke, Ursula Müller-Werdan, Henning Ebelt, Karl Werdan
INTRODUCTION: A heart rate higher than 90 beats/min indicates an unfavorable prognosis for patients with multiple organ dysfunction syndrome (MODS). We sought to investigate the effect of the pacemaker current (If) inhibitor ivabradine on heart rate, hemodynamics, and disease severity among patients with MODS. MATERIAL AND METHODS: In this prospective, controlled, randomized, open-label, two-arm phase II trial, seventy patients with MODS, a sinus rhythm of at least 90 beats/min, and contraindications to β-blocker therapy were randomly assigned to receive the standard treatment ± ivabradine (5 mg twice daily) for 96 h via the enteral route...
September 19, 2017: Shock
https://www.readbyqxmd.com/read/28916091/retraction-notice-to-ivabradine-as-adjuvant-treatment-for-chronic-heart-failure-int-j-cardiol-227-2017-43-50
#16
Carolina C Mizzaci, Gustavo J M Porfírio, André T Vilela, José Cícero S Guillhen, Rachel Riera
No abstract text is available yet for this article.
November 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28903983/ivabradine-in-heart-failure-the-representativeness-of-shift-systolic-heart-failure-treatment-with-the-if-inhibitor-ivabradine-trial-in-a-broad-population-of-patients-with-chronic-heart-failure
#17
COMPARATIVE STUDY
Debraj Das, Gianluigi Savarese, Ulf Dahlström, Michael Fu, Jonathan Howlett, Justin A Ezekowitz, Lars H Lund
BACKGROUND: The sinus node inhibitor ivabradine was approved for patients with heart failure (HF) after the ivabradine and outcomes in chronic HF (SHIFT [Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial]) trial. Our objective was to characterize the proportion of patients with HF eligible for ivabradine and the representativeness of the SHIFT trial enrollees compared with those in the Swedish Heart Failure Registry. METHODS AND RESULTS: We examined 26 404 patients with clinical HF from the Swedish Heart Failure Registry and divided them into SHIFT type (left ventricular ejection fraction <40%, New York Heart Association class II-IV, sinus rhythm, and heart rate ≥70 beats per minute) and non-SHIFT type...
September 2017: Circulation. Heart Failure
https://www.readbyqxmd.com/read/28880025/expert-consensus-document-a-diamond-approach-to-personalized-treatment-of-angina
#18
REVIEW
Roberto Ferrari, Paolo G Camici, Filippo Crea, Nicolas Danchin, Kim Fox, Aldo P Maggioni, Athanasios J Manolis, Mario Marzilli, Giuseppe M C Rosano, José L Lopez-Sendon
In clinical guidelines, drugs for symptomatic angina are classified as being first choice (β-blockers, calcium-channel blockers, short-acting nitrates) or second choice (ivabradine, nicorandil, ranolazine, trimetazidine), with the recommendation to reserve second-choice medications for patients who have contraindications to first-choice agents, do not tolerate them, or remain symptomatic. No direct comparisons between first-choice and second-choice treatments have demonstrated the superiority of one group of drugs over the other...
September 7, 2017: Nature Reviews. Cardiology
https://www.readbyqxmd.com/read/28878030/the-hyperpolarization-activated-cyclic-nucleotide-gated-channels-from-biophysics-to-pharmacology-of-a-unique-family-of-ion-channels
#19
REVIEW
Laura Sartiani, Guido Mannaioni, Alessio Masi, Maria Novella Romanelli, Elisabetta Cerbai
Hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels are important members of the voltage-gated pore loop channels family. They show unique features: they open at hyperpolarizing potential, carry a mixed Na/K current, and are regulated by cyclic nucleotides. Four different isoforms have been cloned (HCN1-4) that can assemble to form homo- or heterotetramers, characterized by different biophysical properties. These proteins are widely distributed throughout the body and involved in different physiologic processes, the most important being the generation of spontaneous electrical activity in the heart and the regulation of synaptic transmission in the brain...
October 2017: Pharmacological Reviews
https://www.readbyqxmd.com/read/28859790/ivabradine-in-children-with-dilated-cardiomyopathy-and-symptomatic-chronic-heart-failure
#20
RANDOMIZED CONTROLLED TRIAL
Damien Bonnet, Felix Berger, Eero Jokinen, Paul F Kantor, Piers E F Daubeney
BACKGROUND: Heart rate reduction as a therapeutic target has been investigated in adults with heart failure (HF). Ivabradine has shown promising efficacy, but has not been evaluated in children. Currently, treatment recommendations for chronic pediatric HF are based mainly on chronic HF guidelines for adults. OBJECTIVES: The authors explored the dose-response relationship of ivabradine in children with dilated cardiomyopathy and symptomatic chronic HF. The primary endpoint was ≥20% reduction in heart rate from baseline without inducing bradycardia or symptoms...
September 5, 2017: Journal of the American College of Cardiology
keyword
keyword
6588
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"